Consolidated Revenue Surges 143.5%, Operating Loss Narrows... Net Loss Widens
-
Revenue 651.4 billion won, up 143.5% YoY (subsidiary performance improvement)
-
Operating loss 123.5 billion won, loss margin narrowed 10.8%
-
Net loss 56.2 billion won, widened 12.1% YoY
-
Total assets 2.94 trillion won, liabilities 907.3 billion won, equity 2.04 trillion won
-
Large corporation; provisional results before external audit
KOSPI Filing Information
-
Filing: Change in Sales or Profit Structure of 30% (15% for Large Corporations) or More
-
Company: SK Bioscience (302440)
-
Submission: SK Bioscience Co.,Ltd
-
Receipt: 02-03-2026
-
Under KRX KOSPI Market Division